Stocks making the biggest moves midday: Amgen, Qualcomm, Expedia, CoreWeave & more
Stryker (-7%) faces supply constraints; Amgen (-10%) slides after Novartis' drug trial results. Qualcomm (+4%) partners with AWS. AI-linked stocks surge: CoreWeave (+15%), Lumentum (+12%), Coherent (+9%). Travel stocks fall as gasoline futures rise. Roivant (+20%) reports positive trial results. Lockheed (+3%) upgraded by UBS. Novartis (-13%) faces third drug-trial setback. Peloton (-5%) downgraded by Morgan Stanley. Boston Scientific (-5%) hit by cyberattack. Bloom Energy (+10%) set to join S&P
How this was made
The 30-second read
Why it matters
The mix of operational setbacks, trial results, and strategic partnerships creates a volatile trading environment.
Market read
Multiple sectors experience sharp moves; traders should focus on biotech trial outcomes and tech partnership news.
What to watch
Supply‑chain constraints and regulatory scrutiny could dampen upside for several names.
Background
Midday market roundup highlighting biggest price moves and catalyst‑driven news.
Ticker impact
Amgen slid ~10% after competitor trial disappointment and rating cut to market perform.
Further downside possible if data disappoints.
Market reacts to trial risk and rating downgrade.
Qualcomm jumped 4% after announcing a data‑center partnership with AWS and issuing warrants.
Short‑term upside as partnership details unfold.
New deal provides growth catalyst.
Expedia fell 6% as travel stocks slipped on higher gasoline futures.
Potential further weakness if fuel prices stay elevated.
Broad sector headwind, no company‑specific news.
Stryker dropped >7% due to supply constraints in its peripheral vascular business.
Continued pressure on stock price.
Operational bottleneck impacts earnings outlook.
Lockheed Martin added ~3% after UBS upgraded to buy.
May attract buying interest.
Analyst opinion without new fundamentals.
Novartis tumbled 13% after Phase 3 trial failure for del‑desiran.
Further downside likely if pipeline concerns persist.
Failed trial is a material negative event.
Peloton slid >5% after Morgan Stanley downgraded to underweight.
Pressure may continue pending earnings.
Analyst downgrade without new data.
Boston Scientific fell 5% after reporting a cyberattack likely hurting 2026 targets.
Potential further decline if impact confirmed.
Operational risk material to outlook.
Market effects
AI and quantum sectors gain momentum from government and corporate partnerships.
U.S. equities see broad mid‑day volatility across biotech, tech, and industrials.
US‑focused moves influence global risk sentiment amid AI hype.
Counterpoint
Price spikes may be overblown as many catalysts are already priced in.
Key entities
- governmentU.S. Department of Commerce
Provided minority equity stakes to quantum firms.
- companyAmazon Web Services
Partnered with Qualcomm for data‑center infrastructure.
